Skip Ribbon Commands
Skip to main content
Menu

Laboratory of Genomic Medicine

​Research head:​Dr Joanne NGEOW
​Research team:

​Sock Hoai CHAN

Yi Jun YAP

Siao Ting CHONG

Nur Diana Binte ISHAK

Zoe ANG

Si Ming FUNG

Jia Min OH

Marsya NADHIRAH


The Laboratory of Genomic Medicine is newly established in 2018 and is the translational arm of the broader Inherited Cancer and Rare Disease Translational Research Programme led by Dr Joanne Ngeow, who also leads the NCCS’s Cancer Genetic Service (CGS).

CGS provides genetic risk assessments for patients with familial and/or rare and undiagnosed diseases. Their mission is to serve as the expert base in the principles and practice of genetic and genomic medicine by being a single platform for research, academic clinical practice, and education for the NCCS, so that personalised healthcare, based on rigorously researched, validated genetic information, can be incorporated into all healthcare decisions.

CGS serves as a self- and physician-referral–based clinical centre that provides expert genetic risk assessment for a broad array of diseases, education, genetic counselling, targeted gene testing, medical management recommendations and appropriate multi-specialty referrals. It is unique in that the comprehensive clinical practice of medical genetics and genomic medicine is housed under one roof in proximity to the research on which the evidence-based practice of personalised genetic healthcare is performed. All patients and families seen at CGS are offered research enrolment.

The laboratory focuses on inherited and somatic (body cell) mutations that contribute to cancer susceptibility syndromes as well as rare hereditary disorders, such as metabolic and endocrine disorders. Using state-of-the-art sequencing technologies, we search for causal sequence variants in DNA from inherited cells of at-risk individuals, in human tumour genomes, and in the genomes of model organisms to determine novel susceptibility genes and to better understand gene–gene and gene–environmental interactions. There is a paucity of such data in Asia and in Singapore. Since 2014, the team has published on the role of genetic predisposition in young breast, colon, sarcoma, endometrial, and childhood cancers, and is currently exploring ways to exploit these insights for therapy.


Selected publications

  1. Ngeow J, Stanuch K, Mester J, et al. Second malignant neoplasms (SMN) in Cowden Syndrome patients with underlying germline PTEN mutations. J Clin Oncol. 2014;32:1818–1824.
  2. Ngeow J, Yu W, Yehia L, et al. Exome sequencing reveals germline SMAD9
    mutation that reduces PTEN expression and is associated with hamartomatous polyposis and gastrointestinal ganglioneuromas. Gastroenterology. 2015;149:886–889.
  3. Ngeow J, Liu C, Zhou K, et al. Detecting germline PTEN mutations among at-risk
    patients with cancer: An age- and sexspecific cost-effectiveness analysis. J Clin Oncol. 2015;33:2537–2544. [Featured on Hematology/ Oncology Today.]
  4. Ho SS, Zhang WY, Tan NY, et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity. 2016;17;44:1177–1189.
  5. Li ST, Yuen J, Zhou K, et al. Impact of subsidies on cancer genetic testing uptake in Singapore. J Med Genet. 2017;54:254–259. [Featured in Economist Intelligence Unit Case Study: Value Based Healthcare: Singapore Building on Excellence, 2017 and a model of care being considered by the Ministry of Health for genetic testing funding.]